Luphere depot
ApprovedSmall molecule
Daewoong Pharmaceutical Co. LTD.Luphere depot is one of 14 small molecule programs targeting Precocious Puberty. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Precocious Puberty
#DrugCompanyPhaseTrials
1Trelstar
OOncoVerity, Inc.
Approved
Casodex
IIstituto Clinico Humanitas
Approved
Faslodex
FFresenius Kabi Oncology Ltd.
Approved
Arimidex
IIstituto Clinico Humanitas
Approved
Triptorelin Pamoate
IpsenPhase 3
Aldactone
PfizerPhase 2
Luphere depot
Daewoong Pharmaceutical Co. LTD.Approved
Femara
NovartisPhase 1
Teslac
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Lupron
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Precocious Puberty1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Luphere depot. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details